Denmark-based vaccines company Bavarian Nordic A/S (CPH:BAVA) on Monday published an update on its share buy-back programme launched on 1 September 2026, under which the company will repurchase shares for an amount up to DKK250m in September and October 2026.
As of 18 September 2026, the company had repurchased a total of 401,322 shares at an average price of DKK210.19 per share, for a total value of DKK84,353,084.
Following these transactions, Bavarian Nordic holds a total of 3,959,913 treasury shares, corresponding to 4.996% of the company's share capital.
Northwest Biotherapeutics and NHSBT collaborate to support production of DCVax-L
Bavarian Nordic reports purchases under share buy-back programme
VaxThera partners with Codagenix for next generation yellow fever vaccine advancement
ABEC opens new manufacturing facility in Wilson, NC
4basebio announces expansion of DNA offering for personalised mRNA medicines
Rznomics reports advances in high-efficiency circRNA production in Nucleic Acids Research
EpiVax introduces AI-enhanced models for immunogenicity prediction